What are orphan drugs?
Orphan drugs are pharmaceutical products developed to diagnose, treat, or prevent rare diseases or conditions, often referred to as orphan diseases. These diseases typically affect a small percentage of the population, making the development of treatments for them financially challenging due to limited market potential.
Why are they called “orphan” drugs?
The term “orphan” reflects that these drugs serve small patient populations that historically lacked commercial incentive for development due to limited market size.
How are orphan drugs approved?
In the U.S., the FDA’s Orphan Drug Designation (ODD) provides incentives for development, including:
- Tax credits for clinical trials
- Market exclusivity (7 years post-approval)
- Waived FDA fees
- Assistance in trial design and regulatory guidance
Challenges of Orphan Drugs
For manufacturers, the rarity of these diseases complicates every aspect of orphan drug development. Many pharma companies rely for clinical trial recruitment, enrollment, and early detection of eligible patients once a drug has been developed.
- High Costs: These drugs are often very expensive due to the specialized nature of development and small patient populations.
- Access and Affordability: Ensuring that patients can afford and access these treatments remains a significant challenge.
- Limited Market Size: Manufacturers may face financial risks due to the narrow patient base.
Orphan drugs play a critical role in advancing care for patients with rare diseases, addressing significant unmet medical needs, and improving quality of life for individuals with these conditions.
